Satiety Hormones: How the Gut Tells the Brain to Stop Eating

If ghrelin is the single hormone that makes us hungry, satiety hormones are the larger cast that tells us to stop. These are the body's own peptides, released mostly from the gut as food arrives, and together they signal fullness to the brain. Because they do naturally what weight-loss drugs try to do pharmacologically, they have become one of the most important stories in modern metabolic medicine.

The gut as an endocrine organ

The intestine is the largest hormone-producing organ in the body. Specialized cells scattered through its lining sense nutrients passing by and release peptides into the blood and onto nearby nerves. Those signals travel through the gut-brain axis to the appetite-regulation centers of the hypothalamus and brainstem, shifting the balance from "seek food" to "stop eating." Below are the principal players.

Peptide YY (PYY)

PYY is a 36-amino-acid hormone released from L-cells in the ileum and colon after a meal. Its active form, PYY3-36, acts on the Y2 receptor to reduce appetite. PYY is notable because its levels rise sharply after bariatric surgery, which may partly explain why such procedures reduce hunger. It is an active target for anti-obesity drugs, often as a co-agonist paired with GLP-1. Read more in PYY and satiety.

Cholecystokinin (CCK)

CCK is released from I-cells of the duodenum and jejunum when fat and protein arrive. It has two classic jobs — triggering gallbladder contraction and pancreatic enzyme secretion — and it is also one of the earliest satiety signals, acting through the CCK1 receptor. Its synthetic analog, sincalide (CCK-8), is FDA-approved as a diagnostic to test gallbladder function during imaging. CCK itself is the body's own hormone, not a drug.

Oxyntomodulin

Oxyntomodulin is a 37-amino-acid peptide, also from L-cells, produced from the same proglucagon precursor as GLP-1. It is unusual because it activates both the GLP-1 receptor and the glucagon receptor, so it not only reduces appetite but also increases energy expenditure. This dual action made it the biological template for today's dual and triple co-agonist drugs. See oxyntomodulin for weight loss. Drug analogs of oxyntomodulin remain investigational.

Pancreatic polypeptide (PP)

PP is a 36-amino-acid hormone from the pancreas, a cousin of PYY and NPY in the "PP-fold" family. Released after meals, it reduces appetite and slows gastric emptying through the Y4 receptor. PP is low in Prader-Willi syndrome, a genetic disorder marked by relentless hunger, which has drawn research interest in whether restoring PP signaling could curb appetite.

GLP-1 (in brief)

GLP-1 is the best known of the group because its drug analogs transformed diabetes and obesity care. Released from L-cells, it slows gastric emptying, enhances insulin release (the incretin effect), and reduces appetite. Approved medicines that mimic it include semaglutide, while tirzepatide combines GLP-1 with GIP activity. These are the proof that amplifying the body's satiety signals can meaningfully reduce food intake.

Why it matters

No single satiety hormone acts alone. The brain reads the whole chorus — PYY, CCK, oxyntomodulin, PP, GLP-1, amylin, and others — against the hunger signal from ghrelin, and sets appetite accordingly. That redundancy is why the most effective new drugs increasingly combine mechanisms rather than rely on one. For people interested in the science behind appetite control, the satiety system is where much of the current research is concentrated.

> This article is educational and not medical advice. These are the body's natural hormones; where drug analogs exist, they are prescription or investigational medicines used under clinical supervision.